|Bid||3.6300 x 4000|
|Ask||3.9000 x 4000|
|Day's Range||3.5500 - 3.7500|
|52 Week Range||1.8000 - 8.2500|
|Beta (3Y Monthly)||2.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 21, 2019 - May 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.67|
SAN DIEGO, May 21, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in the upcoming FB.
HENDERSON, NV / ACCESSWIRE / April 18, 2019 / Cannabis stocks were a sea of red on Monday, weighed down by Aphria Inc. after it swung to a wide loss in the third quarter that outweighed a surge in revenue. ...
Cannabidiol (CBD) material from virtually THC-free (
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies. RTX has potential clinical benefits derived from its ability to modulate neurogenic inflammation and afferent nerve signaling commonly associated with chronic degenerative conditions.
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announces positive and better than initially hoped for top line results in a discovery study aimed at exploring potential benefits of resiniferatoxin in controlling neuro-inflammatory processes associated with Parkinson’s disease in a rodent model. Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. Transient receptor potential vanilloid 1 (TRPV1) is involved in pain perception and is highly expressed in sensory neurons.
Biopharmaceutical company Sorrento Therapeutics Inc. has filed lawsuits against Dr. Patrick Soon-Shiong and his NantWorks network of companies, accusing the biotech entrepreneur of engaging in a “catch and kill” plan that ultimately blocked the release of Sorrento’s new cancer drug.
Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.
Complete Enrollment of Phase 2 Trial to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects with Lumbosacral Radiculopathy, a.k.a. All subjects experienced rapid reduction of leg and back pain following two SP-102 injection treatments, with group median for average pain in affected leg reduced over 50% throughout 28 days for each injection (100% response rate). Scilex expects SP-102 to be the first FDA approved non-opioid epidural injections for sciatica with the potential to replace the current 10 to 11 million off-label epidural steroid injections administered each year in the U.S.
How Major Rare Disease Pharma Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 295.22% for Sorrento Therapeutics (SRNE) based on the stock’s
Recent Sorrento Therapeutics news has SRNE stock on a roller coaster ride today.Source: Shutterstock Sorrento Therapeutics (NASDAQ:SRNE) announced today that its majority owned subsidiary Scilex Pharmaceuticals is merging with Semnur Pharmaceuticals. This merger has the two companies coming together in an effort to create a leader in the non-opioid pain medicine market. The new company's name is Scilex Holding CompanyThe Sorrento Therapeutics news means that the company's stake in Scilex Pharmaceuticals is being converted into a new stake at the combined company. This has its 77% stake in Scilex Pharmaceuticals becoming a 58% stake in Scilex Holding Company.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"This transaction is highly synergistic," Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, said in a statement. "Scilex has built up a commercial organization with over 100 highly experienced sales representatives, fully staffed marketing, market access, and medical liaison teams while Semnur has a very exciting Phase 3 compound in non-opioid pain management."Scilex Pharmaceuticals' ZTlido is already performing well in the early months of its commercial release. Semnur also has a compound that is in a Phase 3 trial and could also be a strong win for the newly-merged company. * 7 Beaten-Up Stocks to Buy as They Reverse Course The Sorrento Therapeutics news today has SRNE stock on a wild ride. It started off up up 8% on Friday morning and reached a peak increase of 24% during morning trading. However, the stock is now down 9% as of Friday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Sorrento Therapeutics News: Why SRNE Stock Is On The Move appeared first on InvestorPlace.
Sorrento Therapeutics, Inc. (SRNE) announced today that its majority owned subsidiary Scilex Pharmaceuticals Inc. (Scilex) has closed a transaction to merge with Mountain View, California, based Semnur Pharmaceuticals, Inc. (Semnur) to form a new company, Scilex Holding Company (Scilex Holding). Sorrento’s equity stake in Scilex (77%) has been converted into a 58% stake in Scilex Holding. With Scilex’s lead product ZTlido® (lidocaine topical system 1.8%) ramping rapidly in the early months of commercial launch and Semnur’s lead compound (non-opioid corticosteroid gel) in Phase 3 pivotal studies for the treatment of lumbar radicular pain/sciatica with Fast Track status from the FDA, Scilex Holding is well positioned to become a global leader in non-opioid pain management.
Yuhan) and Sorrento Therapeutics, Inc. (SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor. The mAb blocks the interaction of PD-L1 protein with its receptor PD-1, suppressing the inhibitory signal to T cells and enhancing the killing effect of T cells on tumors.
SAN DIEGO, Feb. 25, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that senior management will provide a corporate overview at the upcoming.
The proceeds of the transaction will be utilized to advance ImmuneOncia’s Phase I and II clinical studies of IMC-001, a PD-L1 monoclonal antibody, as well as to support its earlier stage programs. As a result of this financing, ImmuneOncia is expected to be sufficiently funded in preparation for an initial public offering, which is expected to occur in 2021.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Sorrento Therapeutics,Read More...
NEW YORK, Jan. 31, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / January 22, 2019 / The stock market reached a level toward the end of last year where investors and analysts feared a recession. Some of this fear was over a U.S. China trade ...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the phase 1b study of its non-opioid, afferent nerve ablating drug candidate (resiniferatoxin or “RTX”) for the treatment of pain from osteoarthritis in the knee (intra-articular route of administration) interim data analysis of over 30 patients had positive activity, prompting Sorrento to start planning pivotal studies to start in 2019. Rapid onset of pain relief (day following injection) and sustained clinical benefits (84 days) at the lowest dose tested. The “Phase 1b double-blind study to assess the safety and preliminary efficacy of intra-articular administration of resiniferatoxin versus placebo for the treatment of pain due to moderate to severe osteoarthritis of the knee” was expected to recruit about 40 patients in 5 dose level cohorts or until a maximum tolerated dose (MTD) was reached.
Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (SRNE), today announced that Express Scripts has added ZTlido® (lidocaine topical system) 1.8% to its commercial national formularies representing nearly 30 million lives. ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also referred to as post-shingles pain. “SCILEX worked diligently with Express Scripts to ensure that patients and providers will have access to ZTLIDO, a non-opioid, non-abusive treatment option for post-herpetic neuralgia,” said Mike Sweeting, Vice President, Market Access, Scilex. “Express Scripts’ decision to include ZTLIDO on its national formularies in recognition of the benefit it can provide to patients with post-herpetic neuralgia, or PHN, is an important milestone for SCILEX.
Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (SRNE), today announced that ZTlido® (lidocaine topical system) 1.8% (ZTLIDO) is covered by nearly 100M U.S. insured lives1. ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also referred to as post-shingles pain. “SCILEX has been working closely with pharmacy benefit managers (PBMs) and health plans to help ensure patients and providers have access to ZTLIDO, a non-opioid, non-abusive treatment option for post-herpetic neuralgia,” said Mike Sweeting, Vice President, Market Access, Scilex. ZTLIDO is a topical system product that uses an advanced adhesion technology, providing more efficient lidocaine delivery than Lidoderm® (lidocaine patch 5%)* over a full 12 hours.